Practice parameters for the management of clostridium difficile infection

Diseases of the Colon and Rectum

Volumn 58, Issue 1, 2015, Pages 10-24

  Steele, Scott R ^a   McCormick, James ^a   Melton, Genevieve B ^a   Paquette, Ian ^a   Rivadeneira, David E ^a   Stewart, David ^a   Buie, W Donald ^a   Rafferty, Janice ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLON PERFORATION; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; GASTROINTESTINAL SYMPTOM; HUMAN; ILEOSTOMY; INFECTION CONTROL; INFECTIOUS DIARRHEA; MULTIPLE ORGAN FAILURE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; PEPTOCLOSTRIDIUM DIFFICILE; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PSEUDOMEMBRANOUS COLITIS; SIGMOIDOSCOPY; TREATMENT DURATION; ABDOMINAL SURGERY; CLOSTRIDIUM INFECTIONS; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; PATHOGENICITY; PROCEDURES; RECURRENT DISEASE; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM SURGICAL PROCEDURES; EVIDENCE-BASED MEDICINE; HUMANS; INFECTION CONTROL; PROBIOTICS; RECURRENCE; RISK FACTORS;

EID: 84925582248     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1097/DCR.0000000000000289     Document Type: Article

References (183)

1. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204-210.
2. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
3. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298-304.
4. Johnson S, Clabots CR, Linn FV, et al. Nosocomial Clostridium difficile colonization and disease. Lancet. 1990;336:97-100.
5. Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23:653-659.
6. Hansen G, Blatt S, Brecher SM, Dubberke E, Dorsett P. Clostridium difficile: navigating the testing options for diagnosis. American Association for Clinical Chemistry. Clinical Laboratory News. 2010;36. Available at http://www.aacc.org/publications/cln/archive/2010/july/Pages/SeriesArticle.aspx# Accessed January 15, 2014.
7. Causey MW, Spencer MP, Steele SR. Clostridium difficile enteritis after colectomy. Am Surg. 2009;75:1203-1206.
8. Lesperance K, Causey MW, Spencer M, Steele SR. The morbidity of Clostridium difficile infection following elective colonic resection: results from a national population database. Am J Surg. 2011;201:141-148.
9. Denève C, Janoir C, Poilane I, Fantinato C, Collignon A. New trends in Clostridium difficile virulence and pathogenesis. Int J Antimicrob Agents. 2009;33(suppl 1):S24-S28.
10. He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet. 2013;45:109-113.
11. Kanerva M, Mentula S, Virolainen-Julkunen A, Kärki T, Möttönen T, Lyytikäinen O; Hospital Infection Surveillance Team. Reduction in Clostridium difficile infections in Finland, 2008-2010. J Hosp Infect. 2013;83:127-131.
12. Guyatt G, Gutermen D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest. 2006;129:174-181.
13. Bartlett JG, Chang TW, Gurwith M, et.al. Antibiotic-associated pseudomembranous colitis due to toxin producing clostridia. N Engl J Med. 1978;298:531-534.
14. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis in adults: A prospective case-controlled epidemiologic study. Arch Intern Med. 1986;146:95-100.
15. Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982- 1991. Infect Control Hosp Epidemiol. 1994;15:371-381.
16. Schwaber MJ, Simhon A, Block C, et.al. Risk factors for Clostridium difficile carriage and C. difficile-associated disease on the adult wards of an urban tertiary care hospital. Eur J Clin Microbiol Infect Dis. 2000;19:9-15.
17. Morales Chamorro R, Serrano Blanch R, Méndez Vidal MJ, et al. Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. Clin Transl Oncol. 2005;7:258-261.
18. Sanchez TH, Brooks JT, Sullivan PS, et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis. 2005;41:1621-1627.
19. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhea. J Hosp Infect. 2003;54:243-245.
20. Krapohl GL, Morris AM, Cai S, et al. Preoperative risk factors for postoperative Clostridium difficile infection in colectomy patients. Am J Surg. 2013;205:343-347.
21. Rotramel A, Poritz LS, Messaris E, Berg A, Stewart DB. PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics. J Gastrointest Surg. 2012;16:2267-2273.
22. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107:1011-1019.
23. Manabe YC, Vinetz JM, Moore RD, Merz C, Charache P, Bartlett JG. Clostridium difficile colitis: An efficient clinical approach to diagnosis. Ann Intern Med. 1995;123:835-840.
24. Moshkowitz M, Ben Baruch E, Kline Z, Moshe G, Shimoni Z, Konikoff F. Clinical manifestations and outcome of Pseudomembranous colitis in an elderly population in Israel. Isr Med Assoc J. 2004;6:201-204.
25. Abreu MT, Harpaz N. Diagnosis of colitis: making the initial diagnosis. Clin Gastroenterol Hepatol. 2007;5:295-301.
26. Klipfel AA, Schein M, Fahoum B, Wise L. Acute abdomen and Clostridium difficile colitis: Still a lethal combination. Dig Surg. 2000;17:160-163.
27. Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P; West Midlands Research Collaborative. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg. 2012;99:1501-1513.
28. Perera AD, Akbari RP, Cowher MS, et al. Colectomy for fulminant Clostridium difficile colitis: predictors of mortality. Am Surg. 2010;76:418-421.
29. Bassetti M, Villa G, Pecori D, Arzese A, Wilcox M. Epidemiology, diagnosis and treatment of Clostridium difficile infection. Expert Rev Anti Infect Ther. 2012;10:1405-1423.
30. Burkart NE, Kwaan MR, Shepela C, et al. Indications and relative utility of lower endoscopy in the management of Clostridium difficile infection. Gastroenterol Res Pract. 2011;2011:626582.
31. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S12-S18.
32. Nomura K, Fujimoto Y, Yamashita M, et al; Japan Hematology/Oncology Study (J-HOST) Group Kyoto. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol. 2009;44:74-78.
33. Ben-Horin S, Margalit M, Bossuyt P, et al; European Crohn's and Colitis Organization (ECCO). Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis. 2010;4:194-198.
34. Boland GW, Lee MJ, Cats AM, Gaa JA, Saini S, Mueller PR. Antibiotic-induced diarrhea: Specificity of abdominal CT for the diagnosis of Clostridium difficile disease. Radiology. 1994;191:103-106.
35. Boland GW, Lee MJ, Cats AM, Ferraro MJ, Matthia AR, Mueller PR. Clostridium difficile colitis: correlation of CT findings with severity of clinical disease. Clin Radiol. 1995;50:153-156.
36. Macari M, Balthazar EJ, Megibow AJ. The accordion sign at CT: A nonspecific finding in patients with colonic edema. Radiology. 1999;211:743-746.
37. Kawamoto S, Horton KM, Fishman EK. Pseudomembranous colitis: Spectrum of imaging findings with clinical and pathologic correlation. Radiographics. 1999;19:887-897.
38. Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of Clostridium difficile colitis: Should CT guide therapy? AJR Am J Roentgenol. 2001;176:635-639.
39. Ash L, Baker ME, O'Malley CM Jr, Gordon SM, Delaney CP, Obuchowski NA . Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: preva lence and significance of findings. AJR Am J Roentgenol. 2006;186:1393-1400.
40. Vasa CV, Glatt AE. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. Am J Gastroenterol. 2003;98:354-358.
41. Arnold A, Pope C, Bray S, et al. Prospective assessment of two-stage testing for Clostridium difficile. J Hosp Infect. 2010;76:18-22.
42. Butler M, Bliss D, Drekonja D, et al. Effectiveness of Early Diagnosis, Prevention, and Treatment of Clostridium difficile Infection. Comparative Effectiveness Reviews, No. 31. Rockville, MD: Agency for Healthcare Research and Quality (US); December 2011. Available at: http://www.ncbi.nlm.nih.gov/books/NBK83519/. Accessed January 15, 2014.
43. Peterson LR, Olson MM, Shanholtzer CJ, Gerding DN. Results of a prospective, 18-month clinical evaluation of culture, cytotoxin testing, and culturette brand (CDT) latex testing in the diagnosis of Clostridium difficile-associated diarrhea. Diagn Microbiol Infect Dis. 1988;10:85-91.
44. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control. 2009;37:263-270.
45. Cohen SH, Gerding DN, Johnson S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455.
46. Goldenberg SD, Cliff PR, Smith S, Milner M, French GL. Twostep glutamate dehydrogenase antigen real-time polymerase chain reaction assay for detection of toxigenic Clostridium difficile. J Hosp Infect. 2010;74:48-54.
47. Eastwood K, Else P, Charlett A, Wilcox M. Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol. 2009;47:3211-3217.
48. Planche T, Aghaizu A, Holliman R, et al. Diagnosis of Clostridium difficile infection by toxin detection kits: A systematic review. Lancet Infect Dis. 2008;8:777-784.
49. Shetty N, Wren MW, Coen PG. The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: A meta-analysis. J Hosp Infect. 2011;77:1-6.
50. Bamber AI, Fitzsimmons K, Cunniffe JG, Beasor CC, Mackintosh CA, Hobbs G. Diagnosis of Clostridium difficileassociated disease: examination of multiple algorithms using toxin EIA, glutamate dehydrogenase EIA and loop-mediated isothermal amplification. Br J Biomed Sci. 2012;69:112-118.
51. Wilcox MH, Planche T, Fang FC, Gilligan P. What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol. 2010;48:4347-4353.
52. Peterson LR, Robicsek A. Does my patient have Clostridium difficile infection? Ann Intern Med. 2009;151:176-179.
53. Gilligan PH. Is a two-step glutamate dehyrogenase antigen-cytotoxicity neutralization assay algorithm superior to the premier toxin A and B enzyme immunoassay for laboratory detection of Clostridium difficile? J Clin Microbiol. 2008;46:1523-1525.
54. Sloan LM, Duresko BJ, Gustafson DR, Rosenblatt JE. Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. J Clin Microbiol. 2008;46:1996-2001.
55. Gould CV, Edwards JR, Cohen J, et al; Clostridium difficile Infection Surveillance Investigators, Centers for Disease Control and Prevention. Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. Clin Infect Dis. 2013;57:1304-1307.
56. Humphries RM, Uslan DZ, Rubin Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol. 2013;51:869-873.
57. Grein JD, Ochner M, Hoang H, Jin A, Morgan MA, Murthy AR. Comparison of testing approaches for Clostridium difficile infection at a large community hospital. Clin Microbiol Infect. 2014;20:65-69.
58. Catanzaro M, Cirone J. Real-time polymerase chain reaction testing for Clostridium difficile reduces isolation time and improves patient management in a small community hospital. Am J Infect Control. 2012;40:663-666.
59. Larson AM, Fung AM, Fang FC. Evaluation of tcdB real-time PCR in a three-step diagnostic algorithm for detection of toxigenic Clostridium difficile. J Clin Microbiol. 2010;48:124-130.
60. Barnett J, Thomlinson D, Perry C, et al. An audit of the use of manual handling equipment and their microbiological flora: implications for infection control. J Hosp Infect. 1999;43:309-313.
61. Fekety R, Kim KH, Brown D, Batts DH, Cudmore M, Silva J Jr. Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from the hospital environment. Am J Med. 1981;70:906-908.
62. Samore MH, Venkataraman L, DeGirolami PC, et al. Clinical and molecular epidemiology of sporadic and clustered cases of healthcare-associated Clostridium difficile diarrhea. Am J Med. 1996;100:32-40.
63. Savage AM, Alford RH. Healthcare-associated spread of Clostridium difficile. Infect Control. 1983;4:31-33.
64. Sanderson PJ, Weissler S. Recovery of coliforms from the hands of nurses and patients: Activities leading to contamination. J Hosp Infect. 1992;21:85-93.
65. Ojajärvi J. Effectiveness of hand washing and disinfection methods in removing transient bacteria after patient nursing. J Hyg (Lond). 1980;85:193-203.
66. Bobulsky GS, Al-Nassir WN, Riggs MM, Sethi AK, Donskey CJ. Clostridium difficile skin contamination in patients with C. difficile-associated disease. Clin Infect Dis. 2008;46:447-450.
67. Boyce JM, Pittet D; Healthcare Infection Control Practices Advisory Committee. Society for Healthcare Epidemiology of America. Association for Professionals in Infection Control. Infectious Diseases Society of America. Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol. 2002;23(12 suppl):S3-S40.
68. Larson EL, Morton HE. Alcohols. In: Block SS, ed. Disinfection, Sterilization and Preservation, 4th ed. Philadelphia, PA: Lea and Febiger; 1991:642-654.
69. Gershenfeld L. Povidone-iodine as a sporicide. Am J Pharm Sci Support Public Health. 1962;134:78-81.
70. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med. 1990;88:137-140.
71. Dettenkofer M, Seegers S, Antes G, Motschall E, Schumacher M, Daschner FD. Does the architecture of hospital facilities influence nosocomial infection rates? A systematic review. Infect Control Hosp Epidemiol. 2004;25:21-25.
72. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7:526-536.
73. Leffler DA, Lamont JT. Treatment of Clostridium difficile-associated disease. Gastroenterology. 2009;136:1899-1912.
74. Leekha S, Aronhalt KC, Sloan LM, Patel R, Orenstein R. Asymptomatic Clostridium difficile colonization in a tertiary care hospital: Admission prevalence and risk factors. Am J Infect Control. 2013;41:390-393.
75. Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW. Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect Dis. 1994;18:181-187.
76. Marciniak C, Chen D, Stein AC, Semik PE. Prevalence of Clostridium difficile colonization at admission to rehabilitation. Arch Phys Med Rehabil. 2006;87:1086-1090.
77. Simor AE. Diagnosis, management, and prevention of Clostridium difficile infection in long-term care facilities: A review. J Am Geriatr Soc. 2010;58:1556-1564.
78. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007;45:992-998.
79. Simor AE, Yake SL, Tsimidis K. Infection due to Clostridium difficile among elderly residents of a long-term-care facility. Clin Infect Dis. 1993;17:672-678.
80. Walker KJ, Gilliland SS, Vance-Bryan K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc. 1993;41:940-946.
81. Delmée M, Vandercam B, Avesani V, Michaux JL. Epidemiology and prevention of Clostridium difficile infections in a leukemia unit. Eur J Clin Microbiol. 1987;6:623-627.
82. Bender BS, Bennett R, Laughon BE, et al. Is Clostridium difficile endemic in chronic-care facilities? Lancet. 1986;2:11-13.
83. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med. 1992;117:297-302.
84. Gerding DN, Muto CA, Owens RC Jr. Measures to control and prevent Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S43-S49.
85. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S19-S31.
86. Pepin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005;40:1591-1597.
87. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med. 1998;49:375-390.
88. Fekety R, Shah AB. Diagnosis and treatment of Clostridium difficile colitis. JAMA. 1993;269:71-75.
89. Frenz MB, McIntyre AS. Reducing delays in the diagnosis and treatment of Clostridium difficile diarrhoea. QJM. 2003;96:579-582.
90. Kundrapu S, Jury LA, Sitzlar B, Sunkesula VC, Sethi AK, Donskey CJ. Easily modified factors contribute to delays in diagnosis of Clostridium difficile infection: A cohort study and intervention. J Clin Microbiol. 2013;51:2365-2370.
91. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet. 1983;2:1043-1046.
92. Joseph J, Singhal S, Patel GM, Anand S. Clostridium difficile colitis: review of the therapeutic approach (published online ahead of print September 17, 2012). Am J Ther. 2014;21:385-394.
93. Curry SR, Marsh JW, Shutt KA, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis. 2009;48:425-429.
94. O'Connor JR, Galang MA, Sambol SP, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008;52:2813-2817.
95. Bourgault AM, Lamothe F, Loo VG, Poirier L; CDAD-CSI Study Group. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada. Antimicrob Agents Chemother. 2006;50:3473-3475.
96. Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernandez H, Goldstein EJ. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother. 2003;47:2334-2338.
97. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother. 2004;54:211-216.
98. Wenisch C, Parschalk B, Hasenhündl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996;22:813-818.
99. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep. 1995;44:1-13.
100. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997;92:739-750.
101. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
102. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ. 2004;171:466-472.
103. Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg. 2009;144:433-439.
104. Faris B, Blackmore A, Haboubi N. Review of medical and surgical management of Clostridium difficile infection. Tech Coloproctol. 2010;14:97-105.
105. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2011;9:CD004610.
106. Kee VR. Clostridium difficile infection in older adults: A review and update on its management. Am J Geriatr Pharmacother. 2012;10:14-24.
107. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307.
108. Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of Clostridium difficile treatments: A systematic review. Ann Intern Med. 2011;155:839-847.
109. Le F, Arora V, Shah DN, Salazar M, Palmer HR, Garey KW. A real- world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. Pharmacotherapy. 2012;32:129-134.
110. Kim PK, Huh HC, Cohen HW, et al. Intracolonic vancomycin for severe Clostridium difficile colitis. Surg Infect (Larchmt). 2013;14:532-539.
111. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis. 2002;35:690-696.
112. Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-431.
113. Crawford T, Huesgen E, Danziger L. Fidaxomicin: A novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm. 2012;69:933-943.
114. Cornely OA, Crook DW, Esposito R, et al; OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281-289.
115. Lancaster JW, Matthews SJ. Fidaxomicin: The newest addition to the armamentarium against Clostridium difficile infections. Clin Ther. 2012;34:1-13.
116. Whitman CB, Czosnowski QA. Fidaxomicin for the treatment of Clostridium difficile infections. Ann Pharmacother. 2012;46:219-228.
117. Aldape MJ, Packham AE, Nute DW, Bryant AE, Stevens DL. Effects of ciprofloxacin on the expression and production of exotoxins by Clostridium difficile. J Med Microbiol. 2013;62(pt 5):741-747.
118. Lynch T, Chong P, Zhang J, et al; Canadian Nosocomial Infection Surveillance Program (CNISP). Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate. PLoS One. 2013;8:e53757.
119. Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis. 2008;47:56-62.
120. Belmares J, Gerding DN, Parada JP, Miskevics S, Weaver F, Johnson S. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect. 2007;55:495-501.
121. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397.
122. Garimella PS, Agarwal R, Katz A. The utility of repeat enzyme immunoassay testing for the diagnosis of Clostridium difficile infection: A systematic review of the literature. J Postgrad Med. 2012;58:194-198.
123. Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic- Associated diarrhoea. Aliment Pharmacol Ther. 2012;35:1355-1369.
124. Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe. 2009;15:281-284.
125. Guarino A, Lo Vecchio A, Canani RB. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol. 2009;25:18-23.
126. McFarland LV. Evidence-based review of probiotics for antibiotic- Associated diarrhea and Clostridium difficile infections. Anaerobe. 2009;15:274-280.
127. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;1:CD004611.
128. Isakow W, Morrow LE, Kollef MH. Probiotics for preventing and treating nosocomial infections: review of current evidence and recommendations. Chest. 2007;132:286-294.
129. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: A systematic review and meta-analysis. Ann Intern Med. 2012;157:878-888.
130. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5:CD006095.
131. Johnson S, Maziade PJ, McFarland LV, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis. 2012;16:e786-e792.
132. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006;101:812-822.
133. Chan S, Kelly M, Helme S, Gossage J, Modarai B, Forshaw M. Outcomes following colectomy for Clostridium difficile colitis. Int J Surg. 2009;7:78-81.
134. Jaber MR, Olafsson S, Fung WL, Reeves ME. Clinical review of the management of fulminant clostridium difficile infection. Am J Gastroenterol. 2008;103:3195-3204.
135. Stewart DB, Hollenbeak CS, Wilson MZ. Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review. Colorectal Dis. 2013;15:798-804.
136. Osman KA, Ahmed MH, Hamad MA, Mathur D. Emergency colectomy for fulminant Clostridium difficile colitis: Striking the right balance. Scand J Gastroenterol. 2011;46:1222-1227.
137. Synnott K, Mealy K, Merry C, Kyne L, Keane C, Quill R. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg. 1998;85:229-231.
138. Chu EW, Ecker BL, Garg M, Divino CM. The surgical management of active ulcerative colitis complicated by Clostridium difficile infection. J Gastrointest Surg. 2013;17:392-396.
139. Navaneethan U, Mukewar S, Venkatesh PG, Lopez R, Shen B. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J Crohns Colitis. 2012;6:330-336.
140. O'Horo J, Safdar N. The role of immunoglobulin for the treatment of Clostridium difficile infection: A systematic review. Int J Infect Dis. 2009;13:663-667.
141. McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006;49:640-645.
142. Butala P, Divino CM. Surgical aspects of fulminant Clostridium difficile colitis. Am J Surg. 2010;200:131-135.
143. Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004;47:1620-1626.
144. Olivas AD, Umanskiy K, Zuckerbraun B, Alverdy JC. Avoiding colectomy during surgical management of fulminant Clostridium difficile colitis. Surg Infect (Larchmt). 2010;11:299-305.
145. Byrn JC, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg. 2008;143:150-155.
146. Markelov A, Livert D, Kohli H. Predictors of fatal outcome after colectomy for fulminant Clostridium difficile Colitis: A 10-year experience. dr.markelov@gmail.com. Am Surg. 2011;77:977-980.
147. Morris LL, Villalba MR, Glover JL. Management of pseudomembranous colitis. Am Surg. 1994;60:548-551.
148. Lipsett PA, Samantaray DK, Tam ML, Bartlett JG, Lillemoe KD. Pseudomembranous colitis: A surgical disease? Surgery. 1994;116:491-496.
149. Koss K, Clark MA, Sanders DS, Morton D, Keighley MR, Goh J. The outcome of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006;8:149-154.
150. Hall JF, Berger D. Outcome of colectomy for Clostridium difficile colitis: A plea for early surgical management. Am J Surg. 2008;196:384-388.
151. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: An alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg. 2011;254:423-427.
152. Optimal Surgical Treatment of Fulminant Clostridium difficile Colitis. NCT01441271. Available at: http://clinicaltrials.gov/ct2/show/NCT01441271?term=clostridium+difficile&rank=35. Accessed September 2013.
153. Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18(suppl 6):21-27.
154. Musgrave CR, Bookstaver PB, Sutton SS, Miller AD. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis. 2011;15:e438-e448.
155. Johnson S. Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes. J Infect. 2009;58:403-410.
156. O'Horo JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent Clostridium difficile infection: A systematic review. Infection. 2014;42:43-59.
157. Chaparro-Rojas F, Mullane KM. Emerging therapies for Clostridium difficile infection: focus on fidaxomicin. Infect Drug Resist. 2013;6:41-53.
158. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55(suppl 2):S154-S161.
159. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013;37:122-128.
160. Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN. Rifaximin Redux: Treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe. 2009;15:290-291.
161. Venuto C, Butler M, Ashley ED, Brown J. Alternative therapies for Clostridium difficile infections. Pharmacotherapy. 2010;30:1266-1278.
162. Moncino MD, Falletta JM. Multiple relapses of Clostridium difficile- Associated diarrhea in a cancer patient. Successful control with long-term cholestyramine therapy. Am J Pediatr Hematol Oncol. 1992;14:361-364.
163. Kunimoto D, Thomson AB. Recurrent Clostridium difficile associated colitis responding to cholestyramine. Digestion. 1986;33:225-228.
164. van Nispen tot Pannerden CM, Verbon A, Kuipers EJ. Recurrent Clostridium difficile infection: what are the treatment options? Drugs. 2011;71:853-868.
165. Kapoor K, Chandra M, Nag D, Paliwal JK, Gupta RC, Saxena RC. Evaluation of metronidazole toxicity: A prospective study. Int J Clin Pharmacol Res. 1999;19:83-88.
166. Johnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846-848.
167. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769-1775.
168. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580-585.
169. Persky SE, Brandt LJ. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol. 2000;95:3283-3285.
170. Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: A case series of 12 patients. J Clin Gastroenterol. 2010;44:562-566.
171. Mattila E, Uusitalo-Seppälä R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142:490-496.
172. Brandt LJ. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol. 2013;108:177-185.
173. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA . Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther. 2012;35:865-875.
174. Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent clostridium difficile infection. J Clin Gastroenterol. 2011;45(suppl):S159-S167.
175. Bakken JS, Borody T, Brandt LJ, et al; Fecal Microbiota Transplantation Workgroup. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9:1044-1049.
176. Landy J, Al-Hassi HO, McLaughlin SD, et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther. 2011;34:409-415.
177. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011;53:994-1002.
178. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-415.
179. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol. 2010;8:471-473.
180. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow- up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:1079-1087.
181. Postigo R, Kim JH. Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: A review and pooled analysis. Infection. 2012;40:643-648.
182. Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin. Available at: http://clinicaltrials.gov/ct2/show/NCT01226992?term=clostridium+difficile&rank=24. Accessed July 2014.
183. Burke KE, Lamont JT. Fecal transplantation for recurrent Clostridium difficile infection in older adults: A review. J Am Geriatr Soc. 2013;61:1394-1398.